Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
July 29, 2013 -- Healthcare company electroCore moved into new offices* in Bernards Township, New Jersey in July. The new head office facilities will also include an assembly plant for their electroceutical, gammaCore device, which is being relocated from Bermuda.
electroCore, which previously had corporate offices in Morris Plains NJ, is starting to market their first product gammaCore in Germany, the UK, Australia and Canada for the treatment of cluster headache and migraine.
In the US, electroCore is running two FDA approved double blind, randomized, sham control studies to support approval of the therapy. These trials are part of a global program of trials – one of the largest clinical programs currently being run in headache.
electroCore’s breakthrough is the development of a technology that non-invasively stimulates the afferent fibers of the vagus nerve. This stimulation of the vagus nerve, which projects into the brain stem, causes the release of inhibitory neurotransmitters in the central nervous system, including GABA, serotonin, and norepinephirine. These neurotransmitters are known to play a role in a wide range of conditions including migraine and cluster headaches.
electroCore has offices in Canada, Germany, UK and Australia.
- To download images of electroCore’s new offices visit - https://www.hightail.com/download/bWJwOGNjQ1A4Q1RMYnRVag
Help employers find you! Check out all the jobs and post your resume
July 29, 2013 -- Healthcare company electroCore moved into new offices* in Bernards Township, New Jersey in July. The new head office facilities will also include an assembly plant for their electroceutical, gammaCore device, which is being relocated from Bermuda.
electroCore, which previously had corporate offices in Morris Plains NJ, is starting to market their first product gammaCore in Germany, the UK, Australia and Canada for the treatment of cluster headache and migraine.
In the US, electroCore is running two FDA approved double blind, randomized, sham control studies to support approval of the therapy. These trials are part of a global program of trials – one of the largest clinical programs currently being run in headache.
electroCore’s breakthrough is the development of a technology that non-invasively stimulates the afferent fibers of the vagus nerve. This stimulation of the vagus nerve, which projects into the brain stem, causes the release of inhibitory neurotransmitters in the central nervous system, including GABA, serotonin, and norepinephirine. These neurotransmitters are known to play a role in a wide range of conditions including migraine and cluster headaches.
electroCore has offices in Canada, Germany, UK and Australia.
- To download images of electroCore’s new offices visit - https://www.hightail.com/download/bWJwOGNjQ1A4Q1RMYnRVag
Help employers find you! Check out all the jobs and post your resume